Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Taegun Kim
Institution:
Hanmi Pharmaceutical (South Korea)
Observed institutions:
Yonsei University,
Hanmi Pharmaceutical (South Korea)
ORCID:
0009-0005-6637-1669
Observed ORCID:
0009-0005-6637-1669
OpenAlex ID:
A5090301181
Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy
2023
·
Minjee Kim
, Hyeyoung Kim
, et al.
·
Theranostics
·
21
PDF
Propolis suppresses atopic dermatitis through targeting the MKK4 pathway
2024
·
Ye‐Ryeong Cho
, Eui Jeong Han
, et al.
·
BioFactors
·
10
Discovery of Protease-activated receptor 2 antagonists derived from phenylalanine for the treatment of breast cancer
2024
·
Taegun Kim
, Yechan Lee
, et al.
·
Bioorganic Chemistry
·
5
Discovery of PAR2 antagonists through fragment molecular orbital-based hotspot analysis and allosteric sodium site dynamics simulations
2025
·
Junyoung Park
, Hocheol Lim
, et al.
·
Bioorganic Chemistry
·
3
Structural optimization of novel Ras modulator for treatment of Colorectal cancer by promoting β-catenin and Ras degradation
2022
·
Seonghwi Choi
, Hyuntae Kim
, et al.
·
Bioorganic Chemistry
·
2
PDF
Abstract 5782: Machine learning and structure-guided discovery of EP300-selective, orally bioavailable degraders for cancer therapy
2026
·
Ho Yeon Nam
, Sun Young Jang
, et al.
·
Cancer Research
Abstract B117: Discovery of potent, selective, and orally bioavailable heterobifunctional EP300 degraders
2025
·
Yongtaek Lee
, Sun Young Jang
, et al.
·
Molecular Cancer Therapeutics
Show more works
View as search
Works count:
7
Citation count:
41
H-index:
3
I10-index:
2
Year
Topic
Type
